<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OTO</journal-id>
<journal-id journal-id-type="hwp">spoto</journal-id>
<journal-title>Otolaryngology–Head and Neck Surgery</journal-title>
<issn pub-type="ppub">0194-5998</issn>
<issn pub-type="epub">1097-6817</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0194599813486599</article-id>
<article-id pub-id-type="publisher-id">10.1177_0194599813486599</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Head and Neck Surgery</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Head and Neck Cancer Stem Cells</article-title>
<subtitle>The Effect of HPV—An In Vitro and Mouse Study</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Tang</surname><given-names>Alice L.</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0194599813486599">1</xref>
<xref ref-type="aff" rid="aff2-0194599813486599">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Owen</surname><given-names>John H.</given-names></name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="aff1-0194599813486599">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hauff</surname><given-names>Samantha J.</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0194599813486599">1</xref>
<xref ref-type="aff" rid="aff3-0194599813486599">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Park</surname><given-names>Jung Je</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0194599813486599">1</xref>
<xref ref-type="aff" rid="aff4-0194599813486599">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Papagerakis</surname><given-names>Silvana</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0194599813486599">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bradford</surname><given-names>Carol R.</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0194599813486599">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Carey</surname><given-names>Thomas E.</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff1-0194599813486599">1</xref>
<xref ref-type="fn" rid="fn1-0194599813486599">*</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Prince</surname><given-names>Mark E.</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0194599813486599">1</xref>
<xref ref-type="fn" rid="fn1-0194599813486599">*</xref>
</contrib>
</contrib-group>
<aff id="aff1-0194599813486599"><label>1</label>Department of Otolaryngology/Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan, USA</aff>
<aff id="aff2-0194599813486599"><label>2</label>Department of Otolaryngology/Head and Neck Surgery, University of Cincinnati, Cincinnati, Ohio, USA</aff>
<aff id="aff3-0194599813486599"><label>3</label>Division of Otolaryngology/Head and Neck Surgery, University of California San Diego, San Diego, California, USA</aff>
<aff id="aff4-0194599813486599"><label>4</label>Department of Otolaryngology, Institute of Health Sciences, School of Medicine, Gyeongsang National University, Jin Ju, South Korea</aff>
<author-notes>
<corresp id="corresp1-0194599813486599">Mark E. Prince, MD, Department of Otolaryngology/Head and Neck Surgery, University of Michigan, 1500 E. Medical Center Dr, 1903 Taubman Center, SPC 5312, Ann Arbor, MI 48109, USA. Email: <email>mepp@umich.edu</email>
</corresp>
<fn fn-type="equal" id="fn1-0194599813486599">
<label>*</label><p>These authors contributed equally to this article.</p></fn>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2013</year>
</pub-date>
<volume>149</volume>
<issue>2</issue>
<fpage>252</fpage>
<lpage>260</lpage>
<history>
<date date-type="received">
<day>3</day>
<month>12</month>
<year>2012</year>
</date>
<date date-type="rev-recd">
<day>18</day>
<month>2</month>
<year>2013</year>
</date>
<date date-type="accepted">
<day>26</day>
<month>3</month>
<year>2013</year>
</date>
</history>
<permissions>
<copyright-statement>© American Academy of Otolaryngology—Head and Neck Surgery Foundation 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="society">Official journal of the American Academy of Otolaryngology–Head and Neck Surgery Foundation</copyright-holder>
</permissions>
<abstract>
<sec id="section1-0194599813486599">
<title>Objectives</title>
<p>To determine if the behavior of cancer stem cells (CSCs) is affected by human papillomavirus (HPV) status.</p>
</sec>
<sec id="section2-0194599813486599">
<title>Study Design</title>
<p>An in vitro and in vivo analysis of HPV and CSCs.</p>
</sec>
<sec id="section3-0194599813486599">
<title>Setting</title>
<p>University laboratory.</p>
</sec>
<sec id="section4-0194599813486599">
<title>Subjects and Methods</title>
<p>We isolated CSCs from HPV-positive and HPV-negative cell lines. Two HPV-negative cell lines underwent lentiviral transduction of E6/E7. Chemoresistence was determined using colony formation assays. Native HPV-positive and HPV E6/E7-transduced cells were compared for lung colonization after tail vein injection in NOD/SCID mice.</p>
</sec>
<sec id="section5-0194599813486599">
<title>Results</title>
<p>The proportion of CSC is not significantly different in HPV-positive or HPV-negative head and neck squamous cell carcinoma (HNSCC) cell lines. The HNSCC CSCs are more resistant to cisplatin than the non-CSCs, but there were no significant differences between HPV-positive and HPV-negative cells. The HPV-negative cancer cells yielded low colony formation after cell sorting. After transduction with HPV E6/E7, increased colony formation was observed in both CSCs and non-CSCs. Results from tail vein injections yielded no differences in development of lung colonies between HPV E6/E7-transduced cells and nontransduced cells.</p>
</sec>
<sec id="section6-0194599813486599">
<title>Conclusions</title>
<p>Human papillomavirus status does not correlate with the proportion of CSCs present in HNSCC. The HPV-positive cells and those transduced with HPV E6/E7 have a greater clonogenicity than HPV-negative cells. The HNSCC CSCs are more resistant to cisplatin than non-CSCs. This suggests that common chemotherapeutic agents may shrink tumor bulk by eliminating non-CSCs, whereas CSCs have mechanisms that facilitate evasion of cell death. Human papillomavirus status does not affect CSC response to cisplatin therapy, suggesting that other factors explain the better outcomes for patients with HPV-positive cancer.</p>
</sec>
</abstract>
<kwd-group>
<kwd>head and neck cancer</kwd>
<kwd>HPV</kwd>
<kwd>cancer stem cells</kwd>
<kwd>ALDH</kwd>
<kwd>chemotherapy</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Cancer stem cells (CSCs) have been identified in solid tumors and implicated in tumor resistance to therapy.<sup><xref ref-type="bibr" rid="bibr1-0194599813486599">1</xref><xref ref-type="bibr" rid="bibr2-0194599813486599"/>-<xref ref-type="bibr" rid="bibr3-0194599813486599">3</xref></sup> Head and neck squamous cell carcinoma (HNSCC) CSCs have been identified using the cell surface marker CD44 and aldehyde dehydrogenase (ALDH) activity.<sup><xref ref-type="bibr" rid="bibr4-0194599813486599">4</xref><xref ref-type="bibr" rid="bibr5-0194599813486599"/><xref ref-type="bibr" rid="bibr6-0194599813486599"/>-<xref ref-type="bibr" rid="bibr7-0194599813486599">7</xref></sup> Both markers are useful in isolating cells that exhibit the characteristics of CSCs. CD44-expressing cells in HNSCC have an increased metastatic potential, predict tumor aggressiveness, and have increased resistance to agents that induce apoptosis and to irradiation.<sup><xref ref-type="bibr" rid="bibr8-0194599813486599">8</xref><xref ref-type="bibr" rid="bibr9-0194599813486599"/>-<xref ref-type="bibr" rid="bibr10-0194599813486599">10</xref></sup></p>
<p>Studies in other solid tumors have identified ALDH<sup>high</sup> cells as a reliable marker for chemoresistance in cancer cells.<sup><xref ref-type="bibr" rid="bibr11-0194599813486599">11</xref>,<xref ref-type="bibr" rid="bibr12-0194599813486599">12</xref></sup> This property has not yet been explored in HNSCC. The intracellular enzyme ALDH protects cells by oxidizing toxic metabolites.<sup><xref ref-type="bibr" rid="bibr13-0194599813486599">13</xref>,<xref ref-type="bibr" rid="bibr14-0194599813486599">14</xref></sup> Chemoresistance is not unexpected in these cells since ALDH activity also protects against chemotherapeutic agents such as cisplatin and carboplatinum.<sup><xref ref-type="bibr" rid="bibr15-0194599813486599">15</xref></sup></p>
<p>Recognition of high-risk human papillomaviruses (hrHPV) as important etiologic factors in oropharyngeal cancer has led to interest in the role that hrHPV plays in development, progression, and response to therapy in HNSCC. The rise in the incidence of oropharyngeal tumors due to HPV has challenged investigators to explain why HPV-related tumors have favorable patient outcomes. The high-risk HPV oncogenes E6 and E7 derail normal cell cycle pathways through interactions with the critical cell cycle regulators TP53 and retinoblastoma protein (Rb). The papillomaviruses that give rise to squamous cell carcinomas of both the cervix and the head and neck only infect the cells that reside in the basal layer of the mucosa, where normal stem cells exist, and, as recently reported, where ALDH<sup>high</sup>-expressing cells co-localize.<sup><xref ref-type="bibr" rid="bibr6-0194599813486599">6</xref></sup></p>
<p>Using HPV-positive HNSCC cell lines and HPV-negative cell lines transduced with E6 and E7, we evaluated the role of HPV in HNSCC and CSC behavior. Our objectives were to determine if (1) CSCs are more resistant to chemotherapy, (2) HPV status changes CSC behavior, (3) the proportion of CSCs varies in the presence of E6/E7, and (4) the presence of these oncogenes affects the tumorigenicity of the CSCs.</p>
<sec id="section7-0194599813486599" sec-type="materials|methods">
<title>Materials and Methods</title>
<p>IRBMED approval and informed consent were obtained from patients enrolled in the University of Michigan Head and Neck SPORE. The use of animals was approved by the University of Michigan’s Committee for the Humane Use and Care of Animals.</p>
<sec id="section8-0194599813486599">
<title>Cell Culture</title>
<p>Six head and neck cancer cell lines were used: UD-SCC-2, UM-SCC-12, UM-SCC-29, UM-SCC-38, UM-SCC-47, and UM-SCC-74B. UD-SCC-2 and UM-SCC-47 are HPV-positive cell lines. Cells were cultured in standard conditions, including Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen, Carlsbad, California) with 10% fetal bovine serum (FBS). Mycoplasma testing was performed using the Myco Alert Mycoplasma Testing Kit (Lonza, Rockland, Maine). The identity of the cells lines was confirmed by Profiler Plus (Invitrogen) genotyping at 10 polymophic STR loci.</p>
</sec>
<sec id="section9-0194599813486599">
<title>Lentivirus Production and Transduction</title>
<p>UM-SCC-29 and UM-SCC-38 underwent lentiviral transduction: lentivirus packaging vectors (pMDL-RRE, pRSV-REV, pC1-VSVG) were co-transfected with pLentilox–HPV E6/E7–IRES-puromycin or pLentiloxEV-Luciferase proviral plasmid into 293T cells. Supernatants were collected after 72 hours, pelleted, and resuspended (~1 × 10<sup>7</sup> TU/mL). Cell lines were seeded on a 6-well plate (~4 × 10<sup>5</sup> cells/well) 1 day prior to lentiviral transduction with lentivirus-luciferase (labeled now as UM-SCC-29-Luc and UM-SCC-38-Luc). Cell media were changed to 1.2 mL of fresh complete media, 0.3 mL of 10× virus, and 8 µg/mL Polybrene (Sigma, St Louis, Missouri). The cell media were changed to complete media 24 hours after transduction. The cells were expanded and grown for 3 to 4 weeks and then subjected to transduction with lentivirus–HPV E6/E7–IRES-puromycin under the same conditions as above (cell lines now named UM-SCC-29–E6/E7 and UM-SCC-38–E6/E7).</p>
</sec>
<sec id="section10-0194599813486599">
<title>RNA Extraction and Reverse Transcription Polymerase Chain Reaction</title>
<p>RNA was isolated by phenol-chloroform extraction with TRIzol (Invitrogen). Complementary DNA (cDNA) was synthesized using the Reverse Transcription System Kit (Promega, Madison, Wisconsin) according to the manufacturer’s protocol. Primers used to detect E6 and E7 are listed in <xref ref-type="table" rid="table1-0194599813486599"><bold>Table 1</bold></xref>. The HPV-16–containing CaSki cervical cancer cell line was used as a positive control for the presence of oncogenes E6 and E7.</p>
<table-wrap id="table1-0194599813486599" position="float">
<label>Table 1.</label>
<caption>
<p>Primers used for human papillomavirus reverse transcription polymerase chain reaction.</p>
</caption>
<graphic alternate-form-of="table1-0194599813486599" xlink:href="10.1177_0194599813486599-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Primer</th>
<th align="center">Sequence</th>
<th align="center">Product Length, bp</th>
<th align="center">Annealing Temperature, °C</th>
<th align="center">Cycle Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPV16 E6 F<sup><xref ref-type="table-fn" rid="table-fn1-0194599813486599">a</xref></sup>
</td>
<td>ATGCACCAAAAGAGAACTG</td>
<td>476</td>
<td>55</td>
<td>35</td>
</tr>
<tr>
<td>HPV16 E6 R<sup><xref ref-type="table-fn" rid="table-fn1-0194599813486599">a</xref></sup>
</td>
<td>TTACAGCTGGGTTTCTCTAC</td>
<td>476</td>
<td>55</td>
<td>35</td>
</tr>
<tr>
<td>HPV16 E7 F</td>
<td>ACCGGTCGATGTATGTCTTGTTG</td>
<td>360</td>
<td>55</td>
<td>35</td>
</tr>
<tr>
<td>HPV16 E7R</td>
<td>CCGTACCCTCTTCCCCATTG</td>
<td>360</td>
<td>55</td>
<td>35</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0194599813486599">
<label>a</label>
<p>Also amplifies the alternate transcripts E6*I and E6*II.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section11-0194599813486599">
<title>Flow Cytometry and Cell Sorting</title>
<p>Cancer stem cell identification and isolation were performed using the enzymatic reaction involving ALDH using the ALDEFLUOR kit (STEMCELL Technologies, Vancouver, Canada). Two samples were used for controls. Flow cytometry gates were set using the inhibited control and the cell viability sample. An equal number of the ALDH<sup>low</sup>-expressing cells and ALDH<sup>high</sup>-expressing cells were collected.</p>
</sec>
<sec id="section12-0194599813486599">
<title>Multicellular Spheroid Formation</title>
<p>Cells were suspended in DMEM/F12 (Invitrogen) without serum. Additives included 20 ng/µL fibroblast growth factor, 10 ng/µL epidermal growth factor, and B-27 without retinyl acetate (GIBCO, Carlsbad, California). Cells were plated in 6-well ultra-low-attachment culture plates (Corning, Tewksbury, Massachusetts). To determine if spheroids were able to recapitulate the original monolayer phenotype, spheroids were placed back into standard culture plates with complete media containing 10% FBS. For the limiting dilution experiments, UM-SCC-47, UM-SCC-29, and UM-SCC-74B were diluted to a ratio of 1 cell per 10 µL and plated at various densities using 96-well ultra-low-attachment culture plates. Cells were observed for spheroid growth for more than 30 days.</p>
</sec>
<sec id="section13-0194599813486599">
<title>Evaluating Spheroid Architecture</title>
<p>The UM-SCC-12 cell line was grown in spheroid-promoting conditions for 7 days at a cell density of 5 × 10<sup>5</sup> cells in ultra-low-adherence plates. Spheroids were fixed in 70% ethanol resuspended in Histogel (Thermo Scientific, Waltham, Massachusetts). The pellet was then embedded, sectioned, and stained with hematoxylin and eosin.</p>
</sec>
<sec id="section14-0194599813486599">
<title>Colony Formation Assays</title>
<p>The CSC and non-CSC populations were plated at a cell density of 250 cells per 2.0 cm<sup>2</sup> for the following cell lines: UD-SCC-2, UM-SCC-38–Luc, UM-SCC-47, and UM-SCC-38–E6/E7. For UM-SCC-29–Luc and UM-SCC-29–E6/E7, 500 cells per 2.0 cm<sup>2</sup> were plated. Cells were allowed to attach overnight and treated with cisplatin. Complete DMEM was used to dilute the stock concentration of cisplatin to desired doses. Treatment with cisplatin lasted for 12 hours. Cultures were observed for 7 to 14 days to allow for untreated cells to reach more than 50 cells per colony. They were fixed and stained with crystal violet in 20% methanol. Plating efficiency (PE) was calculated by dividing the number of colonies formed in the no-treatment group by the number of cells seeded. Survival fraction (SF) was determined by colonies formed after treatment divided by the number of cells seeded multiplied by the PE. The Student <italic>t</italic> test determined statistical significance.</p>
</sec>
<sec id="section15-0194599813486599">
<title>Tail Vein Injections</title>
<p>Nonobese diabetic severe combined immunodeficient (NOD/SCID) mice were injected and assessed for lung lesions by bioluminescent imaging. Four mice were injected for each cell line: UM-SCC-29–Luc, UM-SCC-29–E6/E7, UM-SCC-38–Luc, and UM-SCC-38–E6/E7. Cells were suspended in phosphate-buffered saline (PBS; GIBCO) for 50,000-cell and 25,000-cell injections. Mice without positive bioimaging of lung tumors were euthanized and the lungs sectioned to confirm the absence of metastasis.</p>
</sec>
<sec id="section16-0194599813486599">
<title>Bioluminescence Imaging</title>
<p>Animals with tumor cell injections were imaged with the Xenogen IVIS-200 (PerkinElmer, Waltham, Massachusetts) imaging system. Treated mice were given intraperitoneal luciferin before being imaged.</p>
</sec>
</sec>
<sec id="section17-0194599813486599" sec-type="results">
<title>Results</title>
<sec id="section18-0194599813486599">
<title>E6/E7 Transduction</title>
<p>Transduction of E6 and E7 oncogenes was verified by comparing cDNA from UM-SCC-38–E6/E7 and UM-SCC-29–E6/E7 with the E6/E7-containing CaSki cell line by reverse transcription polymerase chain reaction (<xref ref-type="fig" rid="fig1-0194599813486599"><bold>Figure 1A</bold></xref>). The HPV-positive cell lines, UD-SCC-2 and UM-SCC-47, displayed E6 and E7; the HPV-negative cell lines, UM-SCC-29 and UM-SCC-38, did not (<xref ref-type="fig" rid="fig1-0194599813486599"><bold>Figure 1B</bold></xref>). E6 appeared as 2 bands for both cell lines representing a full-length E6 gene product (476 base pairs) and an internally spliced variant E6* (297 base pairs). The amplicon size for E7 was 400 base pairs.</p>
<fig id="fig1-0194599813486599" position="float">
<label>Figure 1.</label>
<caption>
<p>(A) Transduction of E6 and E7 oncogenes into UMSCC-38 and UMSCC-29. (B) UD-SCC-2 and UM-SCC-47 display E6 and E7; the HPV-negative cell line, UM-SCC-38, does not.</p>
</caption>
<graphic xlink:href="10.1177_0194599813486599-fig1.tif"/>
</fig>
</sec>
<sec id="section19-0194599813486599">
<title>Proportion of ALDH<sup>high</sup> Cells</title>
<p>Six cell lines were analyzed and sorted for ALDH<sup>high</sup> populations in at least 3 separate trials (<xref ref-type="fig" rid="fig2-0194599813486599"><bold>Figure 2</bold></xref>). All cell lines had ALDH activity when analyzed by fluorescence-activated cell sorting. The mean (standard error [SE]) ALDH<sup>high</sup> population was 1.85% (0.48%) in UD-SCC-2, 13.51% (2.09%) in UM-SCC-47, 1.70% (–0.29%) in UM-SCC-38–E6/E7, 4.11% (2.42%) in UM-SCC-29–E6/E7, 3.52% (0.81%) in UM-SCC-38, and 8.10% (1.65%) in UM-SCC-29 (<xref ref-type="fig" rid="fig2-0194599813486599"><bold>Figure 2B</bold></xref>). When HPV-positive cell lines were averaged, including those cell lines transfected with E6/E7, the mean (SE) ALDH<sup>high</sup> population was 5.65% (1.42%), and the HPV-negative average was 5.64% (1.06%). There were no significant differences between the 2 groups (<italic>P</italic> = .91). However, the proportion of ALDH<sup>high</sup> cells decreased after E6 and E7 transfection, from 3.52% to 1.7% and 8.10% to 4.11% for UM-SCC-38 and UM-SCC-29, respectively.</p>
<fig id="fig2-0194599813486599" position="float">
<label>Figure 2.</label>
<caption>
<p>Flow cytometry. (A) Control aldehyde dehydrogenase (ALDH) activity after inhibition with Diethylaminobenzaldehyde (DEAB; left). (left). ALDH<sup>high</sup> population (right). (B) Percentage of ALDH<sup>high</sup> in cell lines. HPV, human papillomavirus.</p>
</caption>
<graphic xlink:href="10.1177_0194599813486599-fig2.tif"/>
</fig>
</sec>
<sec id="section20-0194599813486599">
<title>Chemoresistance</title>
<p>Cell lines (both HPV positive, HPV negative, and E6/E7 transduced) were treated with graded concentrations of cisplatin and assessed for changes in colony formation. For HPV-positive cell lines UM-SCC-47 and UD-SCC-2, there was a statistically significant higher survival fraction in the ALDH<sup>high</sup> cell population compared with the ALDH<sup>low</sup> population at the following cisplatin concentrations: 0.3125, 0.625, 1.25, and 2.5 µM (<italic>P</italic> &lt; .03) (<xref ref-type="fig" rid="fig3-0194599813486599"><bold>Figure 3A</bold></xref>,<xref ref-type="fig" rid="fig3-0194599813486599"><bold>C</bold></xref>). For the HPV-negative cell line UM-SCC-38, only at the 1.25-µM cisplatin concentration did the ALDH<sup>high</sup> cells have a significantly higher survival fraction than the ALDH<sup>low</sup> cell population (<italic>P</italic> &lt; .01) (<xref ref-type="fig" rid="fig3-0194599813486599"><bold>Figure 3B</bold></xref>). In the transduced cell line UM-SCC-29–E6/E7, there was a significantly higher survival fraction of ALDH<sup>high</sup> cells only at the 0.625-µM cisplatin concentration (<italic>P</italic> &lt; .01) (<xref ref-type="fig" rid="fig3-0194599813486599"><bold>Figure 3D</bold></xref>). No significant differences in survival were evident between the ALDH<sup>high</sup> and ALDH<sup>low</sup> cells for the transduced cell line UM-SCC-38–E6/E7 at any cisplatin concentration (<xref ref-type="fig" rid="fig3-0194599813486599"><bold>Figure 3E</bold></xref>). Overall, there were no significant differences observed in the cisplatin sensitivity between the HPV-positive and HPV-negative cell lines (<xref ref-type="fig" rid="fig4-0194599813486599"><bold>Figure 4A</bold></xref>). In addition, there were no significant differences in SF of the ALDH<sup>high</sup> and ALDH<sup>low</sup> cell subpopulations sorted from HPV-positive and HPV-negative cell lines (<xref ref-type="fig" rid="fig4-0194599813486599"><bold>Figure 4B</bold></xref>).</p>
<fig id="fig3-0194599813486599" position="float">
<label>Figure 3.</label>
<caption>
<p>Comparison of survival fraction of ALDH-positive (ALDH<sup>high</sup>) and ALDH-negative (ALDH<sup>low</sup>) cells sorted from cell lines and exposed to cisplatin at various concentrations. ALDH, aldehyde dehydrogenase.</p>
</caption>
<graphic xlink:href="10.1177_0194599813486599-fig3.tif"/>
</fig>
<fig id="fig4-0194599813486599" position="float">
<label>Figure 4.</label>
<caption>
<p>(A, B) Comparison of survival fraction between HPV-positive and HPV-negative cell lines at various doses of cisplatin. (C) Colony formation assay. ALDH, aldehyde dehydrogenase; HPV, human papillomavirus.</p>
</caption>
<graphic xlink:href="10.1177_0194599813486599-fig4.tif"/>
</fig>
</sec>
<sec id="section21-0194599813486599">
<title>Clonogenicity</title>
<p>The HPV-negative cell line UM-SCC-29 formed no colonies (<xref ref-type="fig" rid="fig4-0194599813486599"><bold>Figure 4C</bold></xref>). The HPV-negative cell line UM-SCC-38 had very low clonogenicity in all experimental groups. Each of the naturally infected HPV-positive cell lines exhibited greater colony formation ability. In UD-SCC-2, there was a mean (SE) of 18.35 (2.28) and 11.68 (1.78) colonies for ALDH<sup>high</sup> and ALDH<sup>low</sup>, respectively. In UM-SCC-47, there was a mean (SE) of 6.86 (1.35) and 8.19 (1.21) colonies in ALDH<sup>high</sup> and ALDH<sup>low</sup>, respectively. UM-SCC-29 and UM-SCC-38 both exhibited increased in clonogenicity when the cell lines were transfected with E6/E7. For UM-SCC-29–E6/E7, there was a mean (SE) of 3.86 (0.68) and 10.53 (1.1) colonies formed for ALDH<sup>high</sup> and ALDH<sup>low</sup> cells, respectively. Likewise, there was increased clonogenicity in UM-SCC-38–E6/E7, with a mean (SE) of 12.38 (1.11) colonies formed for ALDH<sup>high</sup> and 13.5 (0.80) colonies for ALDH<sup>low</sup> relative to the parental cells.</p>
</sec>
<sec id="section22-0194599813486599">
<title>Self-Renewal</title>
<p>UD-SCC-2, UM-SCC-12, UM-SCC-47, UM-SCC-38, UM-SCC-29, and UM-SCC-74B were tested for their ability to grow as spheroids. All cell lines, with the exception of UD-SCC-2, formed compact spheroids (<xref ref-type="fig" rid="fig5-0194599813486599"><bold>Figure 5</bold></xref>). UD-SCC-2 formed loose cellular aggregates that did not reflect true spherical geometry. UM-SCC-47 and UM-SCC-74B were tested using limiting dilution experiments to determine if single cells were able to form spheroids. No spheroids were observed to form below cell densities of 2500 cells/100 µL, suggesting that spheroid formation does not represent clonal growth but rather aggregation. Spheroids were able to revert back to monolayer cell morphology when plated back in standard culture conditions (<xref ref-type="fig" rid="fig5-0194599813486599"><bold>Figure 5</bold></xref>). When spheroids are sectioned, their morphology more closely resembles tumors than do monolayer cells.</p>
<fig id="fig5-0194599813486599" position="float">
<label>Figure 5.</label>
<caption>
<p>(A) Spheroid formation in a series of cell lines. (B) Spheroids are able to revert back to monolayer cell morphology. (C) Spheroids closely mimic primary tumor morphology. bFGF, basic fibroblast growth factor; DMEM, Dulbecco’s modified Eagle’s medium; EGF, epidermal growth factor; FBS, fetal bovine serum; NEAA, nonessential amino acid.</p>
</caption>
<graphic xlink:href="10.1177_0194599813486599-fig5.tif"/>
</fig>
</sec>
<sec id="section23-0194599813486599">
<title>Tail Vein Injections</title>
<p>Eight mice were injected with each cell line. Four mice in each group were injected with the control-transfected cell lines (UM-SCC-29–Luc and UM-SCC-38–Luc) and 4 mice with the E6/E7-transfected cell lines (UM-SCC-29–E6/E7 and UM-SCC-38–E6/E7) (<xref ref-type="fig" rid="fig6-0194599813486599"><bold>Figure 6</bold></xref>). In the UM-SCC-29–E6/E7 tail vein injections, 1 of 4 mice grew lung lesions with 5 × 10<sup>4</sup> cells after 8 weeks and progressed at 16 weeks. For UM-SCC-29–Luc, there were no lesions at 8 weeks, but lung lesions appeared in 1 of 4 mice at 16 weeks. UM-SCC-38–E6/E7 and UM-SCC-38–Luc did not produce lung lesions up to 16 weeks. The E6/E7 status of the cell line did not alter the ability of the cells to produce lung colonies.</p>
<fig id="fig6-0194599813486599" position="float">
<label>Figure 6.</label>
<caption>
<p>Tail vein injections in nonobese diabetic severe combined immunodeficient mice at 8 and 16 weeks. Bioluminescence reveals lung colonies.</p>
</caption>
<graphic xlink:href="10.1177_0194599813486599-fig6.tif"/>
</fig>
</sec>
</sec>
<sec id="section24-0194599813486599" sec-type="discussion">
<title>Discussion</title>
<p>Numerous treatment strategies have been suggested for patients with advanced HNSCC. Platinum-based therapy is often included in treatment arms. Cisplatin resistance in HNSCC is a major obstacle to treatment despite escalating doses. One explanation for this observation is that the cells surviving chemotherapy acquire resistance. The cancer stem cell hypothesis suggests that treatment failures occur due to ineffective killing of cancer stem cells.<sup><xref ref-type="bibr" rid="bibr16-0194599813486599">16</xref></sup> Our results indicate that the HNSCC CSC fraction represents a very small subset of tumor cells that have increased cell survival after treatment with cisplatin. Four of the 5 cell lines we tested demonstrated increased cell survival in CSCs with exposure to at least 1 concentration of cisplatin. Cancers from other tumor sites have revealed similar findings, showing inherent chemoresistence in ALDH<sup>high</sup>-expressing cells.<sup><xref ref-type="bibr" rid="bibr15-0194599813486599">15</xref></sup> In breast cancer cell lines, Tanei et al<sup><xref ref-type="bibr" rid="bibr17-0194599813486599">17</xref></sup> observed that ALDH<sup>high</sup> cells were more resistant to sequential treatment with paclitaxel- and epirubicin-based chemotherapy than their ALDH<sup>low</sup> counterparts. They also observed that primary tumors had increased expression of ALDH1 cells after neoadjuvant chemotherapy, indicating a higher rate of CSC survival after treatment. In colorectal cancer, inhibition ALDH1 appears to play a role in sensitizing cells to cyclophosphamide.<sup><xref ref-type="bibr" rid="bibr18-0194599813486599">18</xref></sup> Multiple mechanisms have been proposed to explain this resistance in other cancers, including the involvement of the ALDH enzyme itself.<sup><xref ref-type="bibr" rid="bibr14-0194599813486599">14</xref></sup></p>
<p>Expression of CSC markers correlates with worse prognosis and advanced tumor stage in HNSCC and other tumors.<sup><xref ref-type="bibr" rid="bibr10-0194599813486599">10</xref>,<xref ref-type="bibr" rid="bibr19-0194599813486599">19</xref></sup> Conversely, the presence of HPV-16 has proven to be a favorable prognostic indicator in patients with oropharyngeal cancer.<sup><xref ref-type="bibr" rid="bibr20-0194599813486599">20</xref>,<xref ref-type="bibr" rid="bibr21-0194599813486599">21</xref></sup> Although our data showed no differences in the proportion of ALDH<sup>high</sup>-expressing cells between HPV-positive and HPV-negative cell lines, we did observe a decrease in CSC proportion when our 2 HPV-negative cell lines were transduced with the HPV-16 oncogenes E6 and E7. Further studies to test this finding are needed.</p>
<p>Currently, to our knowledge, only 6 HNSCC HPV-positive cell lines have been previously described.<sup><xref ref-type="bibr" rid="bibr22-0194599813486599">22</xref><xref ref-type="bibr" rid="bibr23-0194599813486599"/><xref ref-type="bibr" rid="bibr24-0194599813486599"/>-<xref ref-type="bibr" rid="bibr25-0194599813486599">25</xref></sup> Generally, these cell lines are not representative of the profile of the patients with HPV-associated oropharyngeal cancer, as many come from tumors that exhibit aggressive biological behavior. There are inherent differences in primary tumor biology and, therefore, in the cell lines derived from these primary tumors; thus, comparing CSCs from different cell lines has the inherent problem of intratumoral biologic differences. We hypothesized that transfection of HPV-negative cancer cell lines would allow us to compare cancer cells in which the only difference was the addition of HPV E6 and E7. This model has limitations given that we have transduced cells that already have a cancer phenotype, and therefore the resultant cancer cell line does not directly mimic a tumor arising de novo as a result of HPV infection.</p>
<p>Although our data suggest that HNSCC cancer cells with high ALDH expression may have a survival advantage over low-expressing cells, we did not find differences between HPV-positive and HPV-negative cell lines, including our E6/E7-transduced cell lines. This suggests that HPV status alone does not directly correlate with cisplatin sensitivity. In addition, our results indicate that transduction of E6 and E7 does not alter cisplatin sensitivity. In 1 study of HNSCC, only a modest increase in HPV-positive HNSCC cell line sensitivity was demonstrated between HPV-positive and HPV-negative cell lines in vitro, but in immunocompetent mice, HPV-positive tumors responded better to radiation and cisplatin.<sup><xref ref-type="bibr" rid="bibr26-0194599813486599">26</xref></sup> As we did not identify any differences in cisplatin sensitivity in vitro between HPV-positive cancer cells and E6/E7-transfected cancer cells, this suggests that HPV-positive HNSCC cells lack intrinsic properties that make them more sensitive to cisplatin. These findings indicate that response to therapy in HNSCC associated with HPV involves a complex interplay between therapeutic agents, the antigenic properties of the cancer cells, and the host immune system.<sup><xref ref-type="bibr" rid="bibr26-0194599813486599">26</xref>,<xref ref-type="bibr" rid="bibr27-0194599813486599">27</xref></sup></p>
<p>The presence of transfected and integrated E6/E7 had an impact on cancer cell clonogenicity. After transfection, there was an enhanced ability of the cancer cells to form colonies. UM-SCC-29–Luc underwent anoikis (where cells undergo programmed cell death when detached from the extracellular matrix) after culture in suspension, but when transformed with oncogenes E6/E7, tumor cells were able to resist anoikis and proliferate. Moreover, we found that our 2 naturally infected HPV-positive cell lines formed more colonies than our HPV-negative cell lines. Expression of E6 and E7 induces immortalization in several cell types by inactivating the apoptotic regulators TP53 and Rb.<sup><xref ref-type="bibr" rid="bibr28-0194599813486599">28</xref><xref ref-type="bibr" rid="bibr29-0194599813486599"/>-<xref ref-type="bibr" rid="bibr30-0194599813486599">30</xref></sup> Silencing of E6 and E7 results in apoptosis in HPV-positive HNSCC cell lines.<sup><xref ref-type="bibr" rid="bibr31-0194599813486599">31</xref></sup> The precise biologic mechanisms by which E6 and E7 induce these changes are not fully understood.</p>
<p>Culture in suspension is a method by which the CSC populations can be enriched. When cells are grown in serum-free media and plated on nonadherent flasks, floating spheroids and cellular aggregates form. This technique has been tested in various malignancies, including glioblastomas, breast cancers, and colon cancers.<sup><xref ref-type="bibr" rid="bibr32-0194599813486599">32</xref><xref ref-type="bibr" rid="bibr33-0194599813486599"/>-<xref ref-type="bibr" rid="bibr34-0194599813486599">34</xref></sup> Focus on spheroid cultivation in HNSCCs has been limited. Our spheroid model in HNSCC did not demonstrate the behavior of self-renewal. We based our conditions on work done with glioma spheroids, where additives enhanced cell conditions that fostered self-renewal for those stem cells.<sup><xref ref-type="bibr" rid="bibr32-0194599813486599">32</xref></sup> We speculate that for HNSCC CSC self-renewal, suitable microenvironments that promote single CSC maintenance and expansion may still need to be worked out. Krishnamurthy et al<sup><xref ref-type="bibr" rid="bibr6-0194599813486599">6</xref></sup> recently demonstrated that CSC survival and self-renewal require a niche that involves cell signaling initiated by factors secreted by endothelial cells. Nevertheless, we have demonstrated that the spheroids cultivated as a result of cellular aggregation represent a unique 3-dimensional model that more closely represents the in vivo tumor structure than that of cells grown under adherent culture conditions. We postulate that this model may provide a more accurate method to evaluate anticancer drug efficacy in an in vitro environment.<sup><xref ref-type="bibr" rid="bibr35-0194599813486599">35</xref></sup></p>
<p>Collecting primary HPV-positive tumors and HPV-negative tumors and analyzing the proportion of ALDH<sup>high</sup>-expressing cells would be a more direct method of answering the questions regarding differences between HPV-positive and HPV-negative cancer stem cells. However, fresh tumor taken directly from patients to flow cytometry often yields a low proportion of viable cancer cells, especially given that the biopsy specimens obtained are frequently very small. Thus, data obtained from this method are limited and difficult to reproduce. We chose to use cell lines because they yielded consistent and reproducible results. Our findings will need to be confirmed in a group of primary tumors, and we hope to be able to perform this analysis in the future.</p>
</sec>
<sec id="section25-0194599813486599" sec-type="conclusions">
<title>Conclusion</title>
<p>We provide some evidence that CSCs in HNSCC may be more resistant to cisplatin than non-CSCs. This finding suggests that although cisplatin may shrink the tumor, it may be less effective in eradicating the CSCs, leaving this potent population of cancer cells behind. Human papillomavirus status does not appear to have a significant effect on the proportion of CSCs present in HNSCC or their sensitivity to cisplatin therapy. This indicates that other factors, possibly immune-regulated mechanisms, may be responsible for the favorable outcomes of patients with HPV-associated HNSCC.</p>
</sec>
<sec id="section26-0194599813486599">
<title>Author Contributions</title>
<p><bold>Alice L. Tang</bold>, study design, data collection, data analysis, drafting and revising the article, final approval; <bold>John H. Owen</bold>, study design, data collection, data analysis, drafting and revising the article, final approval; <bold>Samantha J. Hauff</bold>, study design, data collection, data analysis, revising the article, final approval; <bold>Jung Je Park</bold>, study design, data collection, data analysis, revising the article, final approval; <bold>Silvana Papagerakis</bold>, study design, data analysis, revising the article, final approval; <bold>Carol R. Bradford</bold>, study design, data analysis, revising the article, final approval; <bold>Thomas E. Carey</bold>, study conception, study design, data analysis, drafting and revising the manuscript, final approval; <bold>Mark E. Prince</bold>, study conception, study design, data analysis, drafting and revising the manuscript, final approval.</p>
</sec>
<sec id="section27-0194599813486599">
<title>Disclosures</title>
<p><bold>Competing interests:</bold> None.</p>
<p><bold>Sponsorships:</bold> None.</p>
<p><bold>Funding source:</bold> This project was made possible by funding from the University of Michigan Comprehensive Cancer Center, the American Academy of Otolaryngology–Head and Neck Surgery Percy Memorial Award, the Kirschstein National Research Service Award (NRSA) in Advanced Research Training in Otolaryngology (5 T32 DC005356), and a gift from Patricia Korican of Korican Real Estate. Additional support was from NIDCR 1 R01-DE019126, NCI P50 CA97248 (Head and Neck SPORE), NIDCD P30 DC05188 (KHRI Research Center Core grant), and NCI P30 CA46592 (Cancer Center Core Grant). None of the funders had any role in the design, conduct, or interpretation of the above-mentioned experiments.</p>
</sec>
</body>
<back>
<ack>
<p>We thank the Flow Cytometry Core and the Vector Core at the University of Michigan for their help in acquiring these data and Dr T. Hoffman and Dr H. Bier, University of Düsseldorf, for the generous provision of UD-SCC-2.</p>
</ack>
<fn-group>
<fn fn-type="presented-at">
<p>Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.</p>
<p>This article was presented at the 2012 AAO-HNSF Annual Meeting &amp; OTO EXPO; September 9-12, 2012; Washington, DC.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0194599813486599">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rich</surname><given-names>JN</given-names></name>
</person-group>. <article-title>Cancer stem cells in radiation resistance</article-title>. <source>Cancer Res</source>. <year>2007</year>;<volume>67</volume>(<issue>19</issue>):<fpage>8980</fpage>-<lpage>8984</lpage>.</citation>
</ref>
<ref id="bibr2-0194599813486599">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bao</surname><given-names>S</given-names></name>
<name><surname>Wu</surname><given-names>Q</given-names></name>
<name><surname>McLendon</surname><given-names>RE</given-names></name>
<etal/>
</person-group>. <article-title>Glioma stem cells promote radioresistance by preferential activation of the DNA damage response</article-title>. <source>Nature</source>. <year>2006</year>;<volume>444</volume>(<issue>7120</issue>):<fpage>756</fpage>-<lpage>760</lpage>.</citation>
</ref>
<ref id="bibr3-0194599813486599">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hong</surname><given-names>SP</given-names></name>
<name><surname>Wen</surname><given-names>J</given-names></name>
<name><surname>Bang</surname><given-names>S</given-names></name>
<name><surname>Park</surname><given-names>S</given-names></name>
<name><surname>Song</surname><given-names>SY</given-names></name>
</person-group>. <article-title>CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells</article-title>. <source>Int J Cancer</source>. <year>2009</year>;<volume>125</volume>(<issue>10</issue>):<fpage>2323</fpage>-<lpage>2331</lpage>.</citation>
</ref>
<ref id="bibr4-0194599813486599">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Prince</surname><given-names>ME</given-names></name>
<name><surname>Sivanandan</surname><given-names>R</given-names></name>
<name><surname>Kaczorowski</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2007</year>;<volume>104</volume>(<issue>3</issue>):<fpage>973</fpage>-<lpage>978</lpage>.</citation>
</ref>
<ref id="bibr5-0194599813486599">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Clay</surname><given-names>MR</given-names></name>
<name><surname>Tabor</surname><given-names>M</given-names></name>
<name><surname>Owen</surname><given-names>JH</given-names></name>
<etal/>
</person-group>. <article-title>Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase</article-title>. <source>Head Neck</source>. <year>2010</year>;<volume>32</volume>(<issue>9</issue>):<fpage>1195</fpage>-<lpage>1201</lpage>.</citation>
</ref>
<ref id="bibr6-0194599813486599">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Krishnamurthy</surname><given-names>S</given-names></name>
<name><surname>Dong</surname><given-names>Z</given-names></name>
<name><surname>Vodopyanov</surname><given-names>D</given-names></name>
<etal/>
</person-group>. <article-title>Endothelial cell–initiated signaling promotes the survival and self-renewal of cancer stem cells</article-title>. <source>Cancer Res</source>. <year>2010</year>;<volume>70</volume>(<issue>23</issue>):<fpage>9969</fpage>-<lpage>9978</lpage>.</citation>
</ref>
<ref id="bibr7-0194599813486599">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>YC</given-names></name>
<name><surname>Chen</surname><given-names>YW</given-names></name>
<name><surname>Hsu</surname><given-names>HS</given-names></name>
<etal/>
</person-group>. <article-title>Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2009</year>;<volume>385</volume>(<issue>3</issue>):<fpage>307</fpage>-<lpage>313</lpage>.</citation>
</ref>
<ref id="bibr8-0194599813486599">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Davis</surname><given-names>SJ</given-names></name>
<name><surname>Divi</surname><given-names>V</given-names></name>
<name><surname>Owen</surname><given-names>JH</given-names></name>
<etal/>
</person-group>. <article-title>Metastatic potential of cancer stem cells in head and neck squamous cell carcinoma</article-title>. <source>Arch Otolaryngol Head Neck Surg</source>. <year>2010</year>;<volume>136</volume>(<issue>12</issue>):<fpage>1260</fpage>-<lpage>1266</lpage>.</citation>
</ref>
<ref id="bibr9-0194599813486599">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chikamatsu</surname><given-names>K</given-names></name>
<name><surname>Ishii</surname><given-names>H</given-names></name>
<name><surname>Takahashi</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Resistance to apoptosis-inducing stimuli in CD44+ head and neck squamous cell carcinoma cells</article-title>. <source>Head Neck</source>. <year>2012</year>;<volume>34</volume>(<issue>3</issue>):<fpage>336</fpage>-<lpage>343</lpage>.</citation>
</ref>
<ref id="bibr10-0194599813486599">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Joshua</surname><given-names>B</given-names></name>
<name><surname>Kaplan</surname><given-names>MJ</given-names></name>
<name><surname>Doweck</surname><given-names>I</given-names></name>
<etal/>
</person-group>. <article-title>Frequency of cells expressing CD44, a head and neck cancer stem cell marker: correlation with tumor aggressiveness</article-title>. <source>Head Neck</source>. <year>2012</year>;<volume>34</volume>(<issue>1</issue>):<fpage>42</fpage>-<lpage>49</lpage>.</citation>
</ref>
<ref id="bibr11-0194599813486599">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Awad</surname><given-names>O</given-names></name>
<name><surname>Yustein</surname><given-names>JT</given-names></name>
<name><surname>Shah</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>High ALDH activity identifies chemotherapy-resistant Ewing’s sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition</article-title>. <source>PLoS One</source>. <year>2010</year>;<volume>5</volume>(<issue>11</issue>):<fpage>e13943.12</fpage>.</citation>
</ref>
<ref id="bibr12-0194599813486599">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Landen</surname><given-names>CN</given-names><suffix>Jr</suffix></name>
<name><surname>Goodman</surname><given-names>B</given-names></name>
<name><surname>Katre</surname><given-names>AA</given-names></name>
<etal/>
</person-group>. <article-title>Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer</article-title>. <source>Mol Cancer Ther</source>. <year>2010</year>;<volume>9</volume>(<issue>12</issue>):<fpage>3186</fpage>-<lpage>3199</lpage>.</citation>
</ref>
<ref id="bibr13-0194599813486599">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Monroe</surname><given-names>MM</given-names></name>
<name><surname>Anderson</surname><given-names>EC</given-names></name>
<name><surname>Clayburgh</surname><given-names>DR</given-names></name>
<name><surname>Wong</surname><given-names>MH</given-names></name>
</person-group>. <article-title>Cancer stem cells in head and neck squamous cell carcinoma</article-title>. <source>J Oncol</source>. <year>2011</year>;<volume>2011</volume>:<fpage>762780</fpage>.</citation>
</ref>
<ref id="bibr14-0194599813486599">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marchitti</surname><given-names>SA</given-names></name>
<name><surname>Brocker</surname><given-names>C</given-names></name>
<name><surname>Stagos</surname><given-names>D</given-names></name>
<name><surname>Vasiliou</surname><given-names>V</given-names></name>
</person-group>. <article-title>Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily</article-title>. <source>Expert Opin Drug Metab Toxicol</source>. <year>2008</year>;<volume>4</volume>(<issue>6</issue>):<fpage>697</fpage>-<lpage>720</lpage>.</citation>
</ref>
<ref id="bibr15-0194599813486599">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alison</surname><given-names>MR</given-names></name>
<name><surname>Guppy</surname><given-names>NJ</given-names></name>
<name><surname>Lim</surname><given-names>SM</given-names></name>
<name><surname>Nicholson</surname><given-names>LJ</given-names></name>
</person-group>. <article-title>Finding cancer stem cells: are aldehyde dehydrogenases fit for purpose?</article-title> <source>J Pathol</source>. <year>2010</year>;<volume>222</volume>(<issue>4</issue>):<fpage>335</fpage>-<lpage>344</lpage>.</citation>
</ref>
<ref id="bibr16-0194599813486599">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reya</surname><given-names>T</given-names></name>
<name><surname>Morrison</surname><given-names>SJ</given-names></name>
<name><surname>Clarke</surname><given-names>MF</given-names></name>
<name><surname>Weissman</surname><given-names>IL</given-names></name>
</person-group>. <article-title>Stem cells, cancer, and cancer stem cells</article-title>. <source>Nature</source>. <year>2001</year>;<volume>414</volume>(<issue>6859</issue>):<fpage>105</fpage>-<lpage>111</lpage>.</citation>
</ref>
<ref id="bibr17-0194599813486599">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tanei</surname><given-names>T</given-names></name>
<name><surname>Morimoto</surname><given-names>K</given-names></name>
<name><surname>Shimazu</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy for breast cancers</article-title>. <source>Clin Cancer Res</source>. <year>2009</year>;<volume>15</volume>(<issue>12</issue>):<fpage>4234</fpage>-<lpage>4241</lpage>.</citation>
</ref>
<ref id="bibr18-0194599813486599">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dylla</surname><given-names>SJ</given-names></name>
<name><surname>Beviglia</surname><given-names>L</given-names></name>
<name><surname>Park</surname><given-names>IK</given-names></name>
<etal/>
</person-group>. <article-title>Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy</article-title>. <source>PLoS One</source>. <year>2008</year>;<volume>3</volume>(<issue>6</issue>):<fpage>e2428</fpage>.</citation>
</ref>
<ref id="bibr19-0194599813486599">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Liu</surname><given-names>R</given-names></name>
<name><surname>Wang</surname><given-names>X</given-names></name>
<name><surname>Chen</surname><given-names>GY</given-names></name>
<etal/>
</person-group>. <article-title>The prognostic role of a gene signature from tumorigenic breast-cancer cells</article-title>. <source>N Engl J Med</source>. <year>2007</year>;<volume>356</volume>(<issue>3</issue>):<fpage>217</fpage>-<lpage>226</lpage>.</citation>
</ref>
<ref id="bibr20-0194599813486599">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>B</given-names></name>
<name><surname>Cordell</surname><given-names>KG</given-names></name>
<name><surname>Lee</surname><given-names>JS</given-names></name>
<etal/>
</person-group>. <article-title>EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer</article-title>. <source>J Clin Oncol</source>. <year>2008</year>;<volume>26</volume>(<issue>19</issue>):<fpage>3128</fpage>-<lpage>3137</lpage>.</citation>
</ref>
<ref id="bibr21-0194599813486599">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fakhry</surname><given-names>C</given-names></name>
<name><surname>Westra</surname><given-names>WH</given-names></name>
<name><surname>Li</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Improved survival of patients with human papillomavirus–positive head and neck squamous cell carcinoma in a prospective clinical trial</article-title>. <source>J Natl Cancer Inst</source>. <year>2008</year>;<volume>100</volume>(<issue>4</issue>):<fpage>261</fpage>-<lpage>269</lpage>.</citation>
</ref>
<ref id="bibr22-0194599813486599">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ferris</surname><given-names>RL</given-names></name>
<name><surname>Martinez</surname><given-names>I</given-names></name>
<name><surname>Sirianni</surname><given-names>N</given-names></name>
<etal/>
</person-group>. <article-title>Human papillomavirus-16 associated squamous cell carcinoma of the head and neck (SCCHN): a natural disease model provides insights into viral carcinogenesis</article-title>. <source>Eur J Cancer</source>. <year>2005</year>;<volume>41</volume>(<issue>5</issue>):<fpage>807</fpage>-<lpage>815</lpage>.</citation>
</ref>
<ref id="bibr23-0194599813486599">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Steenbergen</surname><given-names>RD</given-names></name>
<name><surname>Hermsen</surname><given-names>MA</given-names></name>
<name><surname>Walboomers</surname><given-names>JM</given-names></name>
<etal/>
</person-group>. <article-title>Integrated human papillomavirus type 16 and loss of heterozygosity at 11q22 and 18q21 in an oral carcinoma and its derivative cell line</article-title>. <source>Cancer Res</source>. <year>1995</year>;<volume>55</volume>(<issue>22</issue>):<fpage>5465</fpage>-<lpage>5471</lpage>.</citation>
</ref>
<ref id="bibr24-0194599813486599">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tang</surname><given-names>AL</given-names></name>
<name><surname>Hauff</surname><given-names>SJ</given-names></name>
<name><surname>Owen</surname><given-names>JH</given-names></name>
<etal/>
</person-group>. <article-title>UM-SCC-104: a new human papillomavirus-16–positive cancer stem cell–containing head and neck squamous cell carcinoma cell line</article-title>. <source>Head Neck</source>. <year>2012</year>;<volume>34</volume>(<issue>10</issue>):<fpage>1480</fpage>-<lpage>1491</lpage>.</citation>
</ref>
<ref id="bibr25-0194599813486599">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brenner</surname><given-names>JC</given-names></name>
<name><surname>Graham</surname><given-names>MP</given-names></name>
<name><surname>Kumar</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines</article-title>. <source>Head Neck</source>. <year>2010</year>;<volume>32</volume>(<issue>4</issue>):<fpage>417</fpage>-<lpage>426</lpage>.</citation>
</ref>
<ref id="bibr26-0194599813486599">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Spanos</surname><given-names>WC</given-names></name>
<name><surname>Nowicki</surname><given-names>P</given-names></name>
<name><surname>Lee</surname><given-names>DW</given-names></name>
<etal/>
</person-group>. <article-title>Immune response during therapy with cisplatin or radiation for human papillomavirus–related head and neck cancer</article-title>. <source>Arch Otolaryngol Head Neck Surg</source>. <year>2009</year>;<volume>135</volume>(<issue>11</issue>):<fpage>1137</fpage>-<lpage>1146</lpage>.</citation>
</ref>
<ref id="bibr27-0194599813486599">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Williams</surname><given-names>R</given-names></name>
<name><surname>Lee</surname><given-names>DW</given-names></name>
<name><surname>Elzey</surname><given-names>BD</given-names></name>
<name><surname>Anderson</surname><given-names>ME</given-names></name>
<name><surname>Hostager</surname><given-names>BS</given-names></name>
<name><surname>Lee</surname><given-names>JH</given-names></name>
</person-group>. <article-title>Preclinical models of HPV+ and HPV– HNSCC in mice: an immune clearance of HPV+ HNSCC</article-title>. <source>Head Neck</source>. <year>2009</year>;<volume>31</volume>(<issue>7</issue>):<fpage>911</fpage>-<lpage>918</lpage>.</citation>
</ref>
<ref id="bibr28-0194599813486599">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alvarez-Salas</surname><given-names>LM</given-names></name>
<name><surname>Cullinan</surname><given-names>AE</given-names></name>
<name><surname>Siwkowski</surname><given-names>A</given-names></name>
<name><surname>Hampel</surname><given-names>A</given-names></name>
<name><surname>DiPaolo</surname><given-names>JA</given-names></name>
</person-group>. <article-title>Inhibition of HPV-16 E6/E7 immortalization of normal keratinocytes by hairpin ribozymes</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1998</year>;<volume>95</volume>(<issue>3</issue>):<fpage>1189</fpage>-<lpage>1194</lpage>.</citation>
</ref>
<ref id="bibr29-0194599813486599">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Munger</surname><given-names>K</given-names></name>
<name><surname>Phelps</surname><given-names>WC</given-names></name>
<name><surname>Bubb</surname><given-names>V</given-names></name>
<name><surname>Howley</surname><given-names>PM</given-names></name>
<name><surname>Schlegel</surname><given-names>R</given-names></name>
</person-group>. <article-title>The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes</article-title>. <source>J Virol</source>. <year>1989</year>;<volume>63</volume>(<issue>10</issue>):<fpage>4417</fpage>-<lpage>4421</lpage>.</citation>
</ref>
<ref id="bibr30-0194599813486599">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wazer</surname><given-names>DE</given-names></name>
<name><surname>Liu</surname><given-names>XL</given-names></name>
<name><surname>Chu</surname><given-names>Q</given-names></name>
<name><surname>Gao</surname><given-names>Q</given-names></name>
<name><surname>Band</surname><given-names>V</given-names></name>
</person-group>. <article-title>Immortalization of distinct human mammary epithelial cell types by human papilloma virus 16 E6 or E7</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1995</year>;<volume>92</volume>(<issue>9</issue>):<fpage>3687</fpage>-<lpage>3691</lpage>.</citation>
</ref>
<ref id="bibr31-0194599813486599">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rampias</surname><given-names>T</given-names></name>
<name><surname>Sasaki</surname><given-names>C</given-names></name>
<name><surname>Weinberger</surname><given-names>P</given-names></name>
<name><surname>Psyrri</surname><given-names>A</given-names></name>
</person-group>. <article-title>E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16–positive oropharyngeal cancer cells</article-title>. <source>J Natl Cancer Inst</source>. <year>2009</year>;<volume>101</volume>(<issue>6</issue>):<fpage>412</fpage>-<lpage>423</lpage>.</citation>
</ref>
<ref id="bibr32-0194599813486599">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>J</given-names></name>
<name><surname>Kotliarova</surname><given-names>S</given-names></name>
<name><surname>Kotliarov</surname><given-names>Y</given-names></name>
<etal/>
</person-group>. <article-title>Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines</article-title>. <source>Cancer Cell</source>. <year>2006</year>;<volume>9</volume>(<issue>5</issue>):<fpage>391</fpage>-<lpage>403</lpage>.</citation>
</ref>
<ref id="bibr33-0194599813486599">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vermeulen</surname><given-names>L</given-names></name>
<name><surname>Todaro</surname><given-names>M</given-names></name>
<name><surname>de Sousa Mello</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2008</year>;<volume>105</volume>(<issue>36</issue>):<fpage>13427</fpage>-<lpage>13432</lpage>.</citation>
</ref>
<ref id="bibr34-0194599813486599">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Charafe-Jauffret</surname><given-names>E</given-names></name>
<name><surname>Ginestier</surname><given-names>C</given-names></name>
<name><surname>Iovino</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature</article-title>. <source>Cancer Res</source>. <year>2009</year>;<volume>69</volume>(<issue>4</issue>):<fpage>1302</fpage>-<lpage>1313</lpage>.</citation>
</ref>
<ref id="bibr35-0194599813486599">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kunz-Schughart</surname><given-names>LA</given-names></name>
<name><surname>Freyer</surname><given-names>JP</given-names></name>
<name><surname>Hofstaedter</surname><given-names>F</given-names></name>
<name><surname>Ebner</surname><given-names>R</given-names></name>
</person-group>. <article-title>The use of 3-D cultures for high-throughput screening: the multicellular spheroid model</article-title>. <source>J Biomol Screen</source>. <year>2004</year>;<volume>9</volume>(<issue>4</issue>):<fpage>273</fpage>-<lpage>285</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>